Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care

Nazha, AzizSekeres, Mikkael A.Komrokji, RamiSteensma, DavidKantarjian, HagopRoboz, GailFenaux, PierrePrebet, ThomasAzarnia, NozarZbyszewski, Patrick S.Fruchtman, Steven M.Santini, ValeriaSilverman, Lewis R.Platzbecker, UweGarcia-Manero, Guillermo2018-03-202017Nazha, A., M. A. Sekeres, R. Komrokji, D. P. Steensma, H. Kantarjian, G. Roboz, P. Fenaux, et al. 2017. “Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care.” Blood Cancer Journal 7 (12): 644. doi:10.1038/s41408-017-0018-7. http://dx.doi.org/10.1038/s41408-017-0018-7.http://nrs.harvard.edu/urn-3:HUL.InstRepos:35014421en-USValidation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive careJournal Article2018-03-2010.1038/s41408-017-0018-7